The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P

Journal of Virology

Volumn 77, Issue 11, 2003, Pages 6580-6584

  Tripp, Ralph A ^a   Dakhama, Azzeddine ^b   Jones, Les P ^a   Barskey, Albert ^a   Gelfand, Erwin W ^b   Anderson, Larry J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CX3C CHEMOKINE; CX3C CHEMOKINE ANTIBODY; FRACTALKINE; GLYCOPROTEIN G ANTIBODY; MONOCLONAL ANTIBODY; SUBSTANCE P; SUBSTANCE P ANTIBODY; THROMBOSPONDIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APNEA; ARTICLE; BREATHING RATE; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; MOUSE; NEWBORN INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RESPIRATION DEPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

ANIMALS; APNEA; CHEMOKINES, CX3C; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; RECEPTORS, CYTOKINE; RECEPTORS, HIV; RESPIRATION; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SUBSTANCE P; VIRAL PROTEINS;

EID: 0038364167     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.11.6580-6584.2003     Document Type: Article

References (47)

1. Balzamo, E., P. Joanny, J. G. Steinberg, C. Oliver, and Y. Jammes. 1996. Mechanical ventilation increases substance P concentration in the vagus, sympathetic, and phrenic nerves. Am. J. Respir. Crit. Care Med. 153:153-157.
2. Bonham, A. C. 1995. Neurotransmitters in the CNS control of breathing. Respir. Physiol. 101:219-230.
3. Bruhn, F. W., S. T. Mokrohisky, and K. McIntosh. 1977. Apnea associated with respiratory syncytial virus infection in young infants. J. Pediatr. 90:382-386.
4. Chen, S., K. B. Bacon, L. Li, G. E. Garcia, Y. Xia, D. Lo, D. A. Thompson, M. A. Siani, T. Yamamoto, J. K. Harrison, and L. Feng. 1998. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J. Exp. Med. 188:193-198.
5. Choi, D. C., and O. J. Kwon. 1998. Neuropeptides and asthma. Curr. Opin. Pulm. Med. 4:16-24.
6. Cockwell, P., S. J. Chakravorty, J. Girdlestone, and C. O. Savage. 2002. Fractalkine expression in human renal inflammation. J. Pathol. 196:85-90.
7. Falsey, A. R., J. J. Treanor, R. F. Betts, and E. E. Walsh. 1992. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40:115-119.
8. Falsey, A. R., and E. E. Walsh. 2000. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 13:371-384.
9. Fuller, R. W., D. L. Maxwell, C. M. Dixon, G. P. McGregor, V. F. Barnes, S. R. Bloom, and P. J. Barnes. 1987. Effect of substance P on cardiovascular and respiratory function in subjects. J. Appl. Physiol. 62:1473-1479.
10. Glezen, W. P., S. B. Greenberg, R. L. Atmar, P. A. Piedra, and R. B. Couch. 2000. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283:499-505.
11. Graham, B. S., T. R. Johnson, and R. S. Peebles. 2000. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 48:237-247.
12. Gray, P. A., J. C. Rekling, C. M. Bocchiaro, and J. L. Feldman. 1999. Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the pre-Botzinger complex. Science 286:1566-1568.
13. Hall, C. B. 2001. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344:1917-1928.
14. Harrison, J. K., Y. Jiang, S. Chen, Y. Xia, D. Maciejewski, R. K. McNamara, W. J. Streit, M. N. Salafranca, S. Adhikari, D. A. Thompson, P. Botti, K. B. Bacon, and L. Feng. 1998. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. USA 95:10896-10901.
15. Haynes, L. M., J. Tonkin, L. J. Anderson, and R. A. Tripp. 2002. Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J. Virol. 76:6873-6881.
16. Holdsworth, S. R., A. R. Kitching, and P. G. Tipping. 2000, Chemokines as therapeutic targets in renal disease. Curr. Opin. Nephrol. Hypertens. 9:505-511.
17. Institute of Medicine. 1986. New vaccine development: establishing priorities, diseases of importance in developing countries. National Academy Press, Washington, D.C.
18. Joos, G. F., K. O. De Swert, and R. A. Pauwels. 2001. Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Eur. J. Pharmacol. 429:239-250.
19. Kotwal, G. J. 2000. Poxviral mimicry of complement and chemokine system components: what's the end game? Immunol. Today 21:242-248.
20. Kurt-Jones, E. A., L. Popova, L. Kwinn, L. M. Haynes, L. P. Jones, R. A. Tripp, E. E. Walsh, M. W. Freeman, D. T. Golenbock, L. J. Anderson, and R. W. Finberg. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1:398-401.
21. Maciejewski-Lenoir, D., S. Chen, L. Feng, R. Maki, and K. B. Bacon. 1999. Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J. Immunol. 163:1628-1635.
22. McFadden, G., A. Lalani, H. Everett, P. Nash, and X. Xu. 1998. Virus-encoded receptors for cytokines and chemokines. Semin. Cell Dev. Biol. 9:359-368.
23. McGillis, J. P., M. L. Organist, and D. G. Payan. 1987. Substance P and immunoregulation. Fed. Proc. 46:196-199.
24. Meucci, O., A. Fatatis, A. A. Simen, and R. J. Miller. 2000. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc. Natl. Acad. Sci. USA 97:8075-8080.
25. Nakai, S., Y. Iikura, K. Akimoto, and K. Shiraki. 1991. Substance P-induced cutaneous and bronchial reactions in children with bronchial asthma. Ann. Allergy 66:155-161.
26. Oh, S. B., P. B. Tran, S. E. Gillard, R. W. Hurley, D. L. Hammond, and R. J. Miller. 2001. Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J. Neurosci. 21:5027-5035.
27. Openshaw, P. J. 1995. Immunopathological mechanisms in respiratory syncytial virus disease. Semin. Immunopathol. 17:187-201.
28. Palmer, J. B., and P. J. Barnes. 1987. Neuropeptides and airway smooth muscle function. Am. Rev. Respir. Dis. 136:S50-S54.
29. Panitch, H. B. 2001. Bronchiolitis in infants. Curr. Opin. Pediatr. 13:256-260.
30. Pernow, B. 1985. Role of tachykinins in neurogenic inflammation. J. Immunol. 135:812s-815s.
31. Piedimonte, G. 2001. Neural mechanisms of respiratory syncytial virus-induced inflammation and prevention of respiratory syncytial virus sequelae. Am. J. Respir. Crit. Care Med. 163:S18-S21.
32. Rameshwar, P. 1997. Substance P: a regulatory neuropeptide for hematopoiesis and immune functions. Clin. Immunol. Immunopathol. 85:129-133.
33. Reynolds, P. N., M. D. Holmes, and R. Scicchitano. 1997. Role of tachykinins in bronchial hyper-responsiveness. Clin. Exp. Pharmacol. Physiol. 24:273-280.
34. Robinson, L. A., C. Nataraj, D. W. Thomas, D. N. Howell, R. Griffiths, V. Bautch, D. D. Patel, L. Feng, and T. M. Coffman. 2000. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J. Immunol. 165:6067-6072.
35. Ruth, J. H., M. V. Volin, G. K. Haines III, D. C. Woodruff, K. J. Katschke, Jr., J. M. Woods, C. C. Park, J. C. Morel, and A. E. Koch. 2001. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 44:1568-1581.
36. Said, S. I. 1987. Influence of neuropeptides on airway smooth muscle. Am. Rev. Respir. Dis. 136:S52-S58.
37. Schwarze, J., M. Makela, G. Cieslewicz, A. Dakhama, M. Lahn, T. Ikemura, A. Joetham, and E. W. Gelfand. 1999. Transfer of the enhancing effect of respiratory syncytial virus infection on subsequent allergic airway sensitization by T lymphocytes. J. Immunol. 163:5729-5734.
38. Shay, D. K., R. C. Holman, G. E. Roosevelt, M. J. Clarke, and L. J. Anderson. 2001. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J. Infect. Dis. 183:16-22.
39. Smith, G. L. 1999. Vaccinia virus immune evasion. Immunol. Lett. 65:55-62.
40. Sparer, T. E., S. Matthews, T. Hussell, A. J. Rae, B. Garcia-Barreno, J. A. Melero, and P. J. Openshaw. 1998. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187:1921-1926.
41. Tebbey, P. W., M. Hagen, and G. E. Hancock. 1998. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188:1967-1972.
42. Tomaki, M., M. Ichinose, M. Miura, Y. Hirayama, H. Yamauchi, N. Nakajima, and K. Shirato. 1995. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. 151:613-617.
43. Tripp, R. A., L. Jones, and L. J. Anderson. 2000. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J. Virol. 74:6227-6229.
44. Tripp, R. A., L. P. Jones, L. M. Haynes, H. Zheng, P. M. Murphy, and L. J. Anderson. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2:732-738.
45. Tripp, R. A., D. Moore, L. Jones, W. Sullender, J. Winter, and L. J. Anderson. 1999. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73:7099-7107.
46. Tripp, R. A., D. Moore, J. Winter, and L. J. Anderson. 2000. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J. Virol. 74:1614-1622.
47. Zhao, Z. S., F. Granucci, L. Yeh, P. A. Schaffer, and H. Cantor. 1998. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 279:1344-1347.